Imaging atherosclerotic plaque inflammation via folate receptor targeting using a novel 18F-folate radiotracer

Molecular Imaging

Volumn 13, Issue 2, 2014, Pages

  Müller, Adrienne ^a,b   Beck, Katharina ^a,b   Rancic, Zoran ^a,b   Müller, Cristina ^a,b   Fischer, Cindy R ^a,b   Betzel, Thomas ^a,b   Kaufmann, Philipp A ^a,b   Schibli, Roger ^a,b   Krämer, Stefanie D ^a,b   Ametamey, Simon M ^a,b  

^a ETH Zurich   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENE EXPRESSION; PATHOLOGY; POLYMERASE CHAIN REACTION; RADIOACTIVE TRACERS; RADIOGRAPHY; TISSUE;

ACTIVATED MACROPHAGES; ATHEROSCLEROTIC LESIONS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; GENE EXPRESSION LEVELS; IMMUNOHISTOCHEMISTRY; NON-INVASIVE IMAGING; QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION;

MACROPHAGES;

CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; FLUORODEOXYGLUCOSE F 18; FOLATE RECEPTOR 2; LEUKOCYTE ANTIGEN;

AGED; ANIMAL; ARTERY; ATHEROSCLEROTIC PLAQUE; BIOLOGICAL MODEL; CHEMISTRY; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; MOLECULAR IMAGING; MOUSE; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARTERIES; FEMALE; FLUORODEOXYGLUCOSE F18; FOLATE RECEPTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR IMAGING; PLAQUE, ATHEROSCLEROTIC;

EID: 84898039681     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2013.00074     Document Type: Article

References (44)

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-25, doi:10.1038/nature10146.
2. Fenyo IM, Gafencu AV. The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis. Immunobiology 2013;218:1376-84, doi:10.1016/j.imbio.2013.06.005.
3. Libby P, DiCarli M, Weissleder R. The vascular biology of atherosclerosis and imaging targets. J Nucl Med 2010;51 Suppl 1:33S-7S, doi:10.2967/jnumed.109. 069633.
4. Lindsay AC, Choudhury RP. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov 2008;7:517-29, doi:10.1038/nrd2588.
5. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 2008;451:953-7, doi:10.1038/nature06803.
6. Xia W, Hilgenbrink AR, Matteson EL, et al. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009;113:438-46, doi:10.1182/blood-2008-04-150789.
7. Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93, doi:10.1016/j.ab.2004.12.026.
8. Antony AC. Folate receptors. Annu Rev Nutr 1996;16:501-21, doi:10.1146/annurev.nu.16.070196.002441.
9. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008;41:120-9, doi:10.1021/ar7000815.
10. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev 2008;27:655-64, doi:10.1007/s10555-008-9155-6.
11. Gent YY, Weijers K, Molthoff CF, et al. Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Res Ther 2013;15: R37, doi:10.1186/ar4191.
12. Turk MJ, Breur GJ, Widmer WR, et al. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum 2002;46:1947-55, doi:10.1002/art.10405.
13. Leamon CP, Parker MA, Vlahov IR, et al. Synthesis and biological evaluation of EC20: a new folate-derived, 99mTc-based radiopharmaceutical. Bioconjug Chem 2002;13:1200-10, doi:10.1021/bc0200430.
14. Reddy JA, Xu LC, Parker N, et al. Preclinical evaluation of 99mTc- EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004;45:857-66.
15. Paulos CM, Turk MJ, Breur GJ, et al. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004;56:1205-17, doi:10.1016/j.addr.2004.01.012.
16. Müller C. Folate-based radiotracers for PET imaging-update and perspectives. Molecules 2013;18:5005-31, doi:10.3390/mole cules18055005.
17. Müller C, Forrer F, Schibli R, et al. SPECT study of folate receptorpositive malignant and normal tissues in mice using a novel 99mTcradiofolate. J Nucl Med 2008;49:310-7, doi:10.2967/jnumed.107.045856.
18. Müller C, Schibli R. Folic acid conjugates for nuclear imaging of folate receptor-positive cancer. J Nucl Med 2011;52:1-4, doi:10.2967/jnumed.110. 076018.
19. Bettio A, Honer M, Müller C, et al. Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors. J Nucl Med 2006;47:1153-60.
20. Ayala-Lopez W, Xia W, Varghese B, et al. Imaging of atherosclerosis in apoliprotein E knockout mice: targeting of a folateconjugated radiopharmaceutical to activated macrophages. J Nucl Med 2010;51:768-74, doi:10.2967/jnumed.109.071324.
21. Winkel LC, Groen HC, van Thiel BS, et al. Folate receptor-targeted single-photon emission computed tomography/computed tomography to detect activated macrophages in atherosclerosis: can it distinguish vulnerable from stable atherosclerotic plaques? Mol Imaging 2013;12:1-5.
22. Jager NA, Westra J, van Dam GM, et al. Targeted folate receptor beta fluorescence imaging as a measure of inflammation to estimate vulnerability within human atherosclerotic carotid plaque. J Nucl Med 2012;53:1222-9, doi:10.2967/jnumed.111.099671.
23. Betzel T, Müller C, Groehn V, et al. Radiosynthesis and preclinical evaluation of 39-aza-29-[18F]fluorofolic acid: a novel PET radiotracer for folate receptor targeting. Bioconjug Chem 2013;24:205-14, doi:10.1021/bc300483a.
24. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation 1995;92:1355-74, doi:10.1161/01.CIR.92.5.1355.
25. Nett PC, Zund G, Pretre R, et al. A 20-year follow-up of internal carotid artery endarterectomy with bifurcation advancement. Thorac Cardiovasc Surg 2000;48:279-84, doi:10.1055/s-2000-7880.
26. Pedretti M, Rancic Z, Soltermann A, et al. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: three clinical-grade fully human antibodies Atherosclerosis 2010;208:382-9, doi:10.1016/j.atherosclerosis.2009.07.043.
27. Redgrave JN, Gallagher P, Lovett JK, et al. Critical cap thickness and rupture in symptomatic carotid plaques: the Oxford Plaque Study. Stroke 2008;39:1722-9, doi:10.1161/STROKEAHA.107.507988.
28. Weitman SD, Weinberg AG, Coney LR, et al. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 1992;52:6708-11.
29. Reber J, Struthers H, Betzel T, et al. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-tobackground contrast. Mol Pharm 2012;9:1213-21.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCt method. Methods 2001;25:402-8, doi:10.1006/meth.2001.1262.
31. Fischer CR, Müller C, Reber J, et al. [18F]Fluoro-deoxy-glucose folate: a novel PET radiotracer with improved in vivo properties for folate receptor targeting. Bioconjug Chem 2012;23:805-13, doi:10.1021/bc200660z.
32. Scholtes VP, Johnson JL, Jenkins N, et al. Carotid atherosclerotic plaque matrix metalloproteinase-12-positive macrophage subpopulation predicts adverse outcome after endarterectomy. J Am Heart Assoc 2012;1:e001040.
33. Furusho Y, Miyata M, Matsuyama T, et al. Novel therapy for atherosclerosis using recombinant immunotoxin against folate receptor beta-expressing macrophages. J Am Heart Assoc 2012;1:e003079.
34. Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013;34:719-28, doi:10.1093/eurheartj/ ehs411.
35. Rudd JH, Myers KS, Bansilal S, et al. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007;50:892-6, doi:10.1016/j.jacc.2007.05.024.
36. Cocker MS, McArdle B, Spence JD, et al. Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see. J Nucl Cardiol 2012;19:1211-25, doi:10.1007/s12350-012-9631-9.
37. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-11, doi:10.1161/01.CIR.0000020548.60110.76.
38. Yun M, Yeh D, Araujo LI, et al. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 2001;26:314-9, doi:10.1097/00003072-200104000- 00007.
39. Hermann S, Starsichova A, Waschkau B, et al. Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability? J Nucl Cardiol 2012;19:609-17, doi:10.1007/s12350-012-9553-6.
40. Schrigten D, Breyholz HJ, Wagner S, et al. A new generation of radiofluorinated pyrimidine-2, 4, 6-triones as MMP-targeted radiotracers for positron emission tomography. J Med Chem 2012;55:223-32, doi:10.1021/jm201142w.
41. Laitinen I, Saraste A, Weidl E, et al. Evaluation of aVb3 integrintargeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging 2009;2:331-8, doi:10.1161/CIRCIMAGING.108.846865.
42. Sarai M, Hartung D, Petrov A, et al. Broad and specific caspase inhibitor-induced acute repression of apoptosis in atherosclerotic lesions evaluated by radiolabeled annexin A5 imaging. J Am Coll Cardiol 2007;50:2305-12, doi:10.1016/j.jacc.2007.08.044.
43. Bates SM, Lister-James J, Julian JA, et al. Imaging characteristics of a novel technetium Tc 99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients with acute deep vein thrombosis or a history of deep vein thrombosis. Arch Intern Med 2003;163:452-6, doi:10.1001/archinte.163.4.452.
44. Moses WW. Fundamental limits of spatial resolution in PET. Nucl Instrum Methods Phys Res A 2011;648 Suppl 1:S236-40, doi:10.1016/j.nima.2010.11.092.